Detection of Mycobacterium Tuberculosis and Rifampicin Resistance by Xpert® MTB/RIF Assay among Presumptive Tuberculosis Patients in Addis Ababa, Ethiopia from 2014 to 2021
Detection of Mycobacterium Tuberculosis and Rifampicin Resistance by Xpert® MTB/RIF Assay among Presumptive Tuberculosis Patients in Addis Ababa, Ethiopia from 2014 to 2021
By: Getu Diriba, Ayinalem Alemu, Habteyes Hailu Tola, Kirubel Eshetu, Bazezew Yenew, Misikir Amare, Biniyam Dagne, Hilina Mollalign, Waganeh Sinshaw, Yeshiwork Abebaw, Getachew Seid, Mengistu Tadesse, Betselot Zerihun, Melak Getu, Shewki Moga, Abyot Meaza, Dinka Fekadu Gamtesa, Zigba Tefera, Amanuel Wondimu, Michael Hailu, Bedo Buta, Muluwork Getahun, Abebaw Kebede
Publication: International Journal of Infectious Diseases; 8 September 2022; DOI: https://doi.org/10.1016/j.ijregi.2022.09.001
Abstract
This study aimed to determine the frequencies and trends of Mycobacterium tuberculosis and rifampicin resistance among presumptive tuberculosis patients in Ethiopia, who were tested using the Xpert MTB/RIF assay between 2014 and 2021.
Data were collected retrospectively from patient registries. Laboratory-based data were extracted from the national tuberculosis (TB) referral laboratory database. All patients referred to the National Tuberculosis Reference Laboratory (NTRL) for TB diagnosis from all over the country between March 1, 2014 and September 30, 2021, and tested using the Xpert MTB/RIF assay, were included. The extracted data were entered into a Microsoft Excel sheet and analyzed by Statistical Package for Social Sciences (SPSS) version 23.